Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CHEMOPREVENTIVE AGENTS - PROTEASE INHIBITORS
Autore:
KENNEDY AR;
Indirizzi:
UNIV PENN,SCH MED,DEPT RADIAT ONCOL PHILADELPHIA PA 19104
Titolo Testata:
Pharmacology & therapeutics
fascicolo: 3, volume: 78, anno: 1998,
pagine: 167 - 209
SICI:
0163-7258(1998)78:3<167:CA-PI>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
BOWMAN-BIRK INHIBITOR; SOYBEAN TRYPSIN-INHIBITOR; C-MYC EXPRESSION; RADIATION TRANSFORMATION INVITRO; PANCREATIC-ENZYME SECRETION; C3H 10T1/2 CELLS; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INDUCED MALIGNANT TRANSFORMATION; PUTATIVE PRENEOPLASTIC LESIONS; PLASMA PROTEINASE-INHIBITORS;
Keywords:
PROTEASE INHIBITOR; CARCINOGENESIS; INFLAMMATION; BOWMAN-BIRK INHIBITOR;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
353
Recensione:
Indirizzi per estratti:
Citazione:
A.R. Kennedy, "CHEMOPREVENTIVE AGENTS - PROTEASE INHIBITORS", Pharmacology & therapeutics, 78(3), 1998, pp. 167-209

Abstract

Certain protease inhibitors, called the anticarcinogenic protease inhibitors in this review, are capable of preventing carcinogenesis in a wide variety of in vivo and in vitro model systems. The anticarcinogenic protease inhibitors are extremely potent agents with the ability toprevent cancer, with some unique characteristics as anticarcinogenic agents. The anticarcinogenic protease inhibitors have the ability to irreversibly suppress the carcinogenic process. They do not have to be continuously present to suppress carcinogenesis. They can be effectivewhen applied in both in vivo and in vitro carcinogenesis assay systems at long time periods after carcinogen exposure, and are effective asanticarcinogenic agents at extremely low molar concentrations. While several different types of protease inhibitors can prevent the carcinogenic process, the most potent of the anticarcinogenic protease inhibitors on a molar basis are those with the ability to inhibit chymotrypsin or chymotrypsin-like proteases. The soybean derived protease inhibitor, Bowman-Birk inhibitor (BBI), is a potent chymotrypsin inhibitor that has been extensively studied for its ability to prevent carcinogenesis in many different model systems. Much of this review is focused on the characteristics of BBI as the anticarcinogenic protease inhibitor, as this is the protease inhibitor that has risen to the human trialstage as a human cancer chemopreventive agent. Part of this review hypothesizes that the Bowman-Birk family of protease inhibitors plays a role in plants similar to that of cr, antichymotrypsin in people. BothBBI and alpha(1)-antichymotrypsin are potent inhibitors of chymotrypsin and chymotrypsin-like enzymes, are highly anti inflammatory, and are thought to play important roles in the defense of their respective organisms. It is believed that BBI will be shown to play a major role in the prevention and/or treatment of several different diseases, in addition to cancer. (C) 1998 Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 10:01:31